PE 22-28 spadin-derived peptide – early TREK-1 data worth watching?
Posted by optimizer_jenna in Research & News - 6 points, 5 comments.
I came across the entry for PE 22-28 on the peptides page and it caught my eye because it is described as a spadin‑derived peptide that blocks the TREK‑1 potassium channel. The page says it has shown rapid antidepressant effects and increased neurogenesis in animal models, but that human safety data are unknown and efficacy in humans is unproven. For me this looks like an interesting mechanistic lead, yet I always want to see some clinical data before getting excited about any compound for mood or cognition.
Have any of you seen a human trial or pilot study on PE 22‑28, or tried it in a research setting? I would love to hear what you think about the risk‑benefit balance at this early stage. Tbh I am leaning towards waiting for more transparency on dosing and side effects before considering any personal experimentation.
Comments
- fasted_scientist: I reckon you are spot on to wait. Ngl, these spadin derivatives always sound brilliant in a lab report, but animal models for mood are a bit of a gamble when you translate them to people. I have not seen any actual human trials for PE 22-28, and the lack of safety data on those potassium channels is a bit worrying. For me, messing with brain chemistry without a clear dosing guide feels like a recipe for disaster. I am quite keen on the idea of increased neurogenesis (if it actually happens), bu
- restlessemma: Yeah, I’ve also scoured ClinicalTrials.gov and PubMed – nada on PE 22‑28 in humans. Until there’s a phase 1 safety run, I’d keep it on the shelf. Imo, the neurogenesis hint is cool but not enough to risk brain‑chem tweaks yet. Eh.
- optimizer_jenna: Thanks restlessemma, I did the same search and found nothing human either. It’s reassuring to hear you’re also holding off until safety data appear. Have you come across any other TREK‑1 blockers with at least some human safety info?
- optimizer_jenna: I actually agree with you about the animal models being a bit of a gamble. It is easy to get excited about neurogenesis, but translating that to human mood is a massive leap. Tbh I am also quite worried about the lack of safety data regarding those potassium channels. Since there is no clear dosing guide, it feels too risky for me right now. Do you think the TREK-1 mechanism is actually a viable target for long term use, or is it too unpredictable?
- curious_scientist: IMO I haven’t run into any other TREK‑1 blockers with published human safety yet. Most of what I’ve seen stays in rodent work. If you find something, let’s compare notes.
Community discussion - research and educational context only. Not medical advice.